Drug intelligence / Profile preview

SB308

Development stage: Preclinical
Lead developer: SanBio
Modality: Cell Therapies

Overview

SB308 is a regenerative cell therapy developed by SanBio Co Ltd. It is designed to treat muscle dystrophy, aiming for muscle regeneration. As a cell therapy, it likely functions by promoting the body's natural regenerative processes, similar to other SanBio pipeline products which involve allogeneic transplantation of modified mesenchymal stem cells to secrete growth factors and attract endogenous stem cells to damaged tissue.

Beyond the preview

Go deeper on SB308.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB308.

Explore the full profile